Growth in the Chinese economy has slowed, and recent Covid-driven lockdowns have weighed on growth. China’s trade is particularly influential and is having an impact Ali Baba (BABA).

The company is set to post F4Q22 earnings on Thursday, May 26, and Truist’s top analyst Youssef Squali thinks any short-term guidance “will likely show continued challenges in various divisions of BABA.”

“While the government is reportedly looking at ways to re-open the economy / accelerate growth, the lack of details / time visibility and the potential success of such measures make it difficult to predict when BABA will resume its own growth, 5-star The analyst further explained. “Meanwhile, management is taking more precautions in managing ST costs while maintaining LT growth priorities.”

Overall, there is no change in the forecast of 200.7 billion RMB (year-on-year 7%) of the squalid income compared to the consensus of 199 billion RMB. But at a time when growth is “materially declining”, Squawley has slashed EBITA estimates on “sustainable high costs” that are largely related to organic investment in new ventures.

Areas of this organic investment include “Taobao Deals, Taobao Live, Short Video, New Retail, Taobao Grocery and Community Group Buying (CGB), especially targeting low-level cities.”

Squali is now looking at EBITA of 14 billion RMB (offering 7% margin) while Consensus is looking for 15 billion RMB. Squawley also lowered its FY23 EBITA estimate – down from the previous 146 billion RMB to 133 billion RMB.

The new numbers are based on different trends observed during the quarter; Growth in the monthly NBS report has been slow – especially in March and April – when the zero-tolerance policy aimed at curbing covid has “boosted an already softening economy” and severely affected people’s mobility.

All in all, Squali BABA has a buy rating on the stock even though the price target has been lowered from $ 180 to $ 132. Investors could sit on a 51% gain if Scully’s forecast goes into the coming months. (To view Scaly’s track record, Click here)

Overall, despite Alibaba’s problems, Street maintains a bullish outlook for the Chinese ecommerce giant; The stock boasts a strong buy consensus rating based on a unanimous 18 buy. Furthermore, at $ 168.79, the average price target makes room for a one-year profit of% 94%. (See Alibaba stock forecast in Tipranx)

To get a better idea of ​​stock trading at attractive valuations, visit the best stocks to buy TipRanks, a newly launched tool that integrates all the equity insights of TipRanks.

Disclaimer: The views expressed in this article are those of the featured analyst only. Content is intended for informational purposes only. It is very important to do your own analysis before making any investment.

China is trying to navigate its largest coronavirus outbreak without the tools it could have adopted months ago, the kind of vaccine that has proven to provide the best protection against the worst outcomes from COVID-19. In early spring 2020, a Chinese pharmaceutical company, Fosun Pharma, delivered an mRNA vaccine made by Pfizer and BioNTech – and finally reached an agreement to produce it. It has not yet been cleared in mainland China, despite being approved for use by separate authorities in Hong Kong and Macau.

Now health experts say delays – putting politics and national pride above public health – can cause unavoidable coronavirus deaths and deep economic losses as entire cities will be locked down to contain the country’s unprotected population. “The biggest problem is the delay in reopening,” said Shi Chen, a health economist at Yale University’s School of Public Health. “The consequences will be huge, the supply chain will be disrupted, all kinds of services will be disrupted.” Studies have consistently shown that vaccines with the mRNA vaccine, developed by Pfizer-BioNTech and Moderna, provide the best protection against hospitalization and death from Covid-19. Older Chinese vaccines have been shown to be relatively effective against the original strain of the virus, but much less so in recent times.

As the evidence becomes clearer, even countries that initially used the Chinese vaccine and some less effective Western-made vaccines are turning to booster shots and the mRNA vaccine for new vaccines. Not China. Regulators have not publicly stated why they did not work – mRNA vaccines have been approved in many parts of the world and have proven safe and effective in millions of people. But a Chinese health official and another directly involved in the talks told the Associated Press that the authorities had backed down because they wanted to master the technology in China and not rely on foreign suppliers. Both spoke on condition of anonymity because of the sensitive nature of the issue.

For more than a year, the method seemed defensible. The country was able to keep the virus better than any other large country through its strict “zero covid” method, which isolates infected people and locks up communities when an infection occurs. But now, the highly contagious Omicron variant is testing that strategy, requiring more extensive and prolonged lockdowns that are taking a greater economic and human toll. While other countries are able to operate closer to normal because their people are protected by vaccines or previous infections, China has only its lockdown strategy left to avoid large numbers of hospitalizations and deaths.

China may be changing its mind. The Communist Party-owned Global Times reported last month that Fosun Pharma was still working with health authorities for its approval, and that Shanghai authorities had recently issued a new policy that would allow the import of the COVID-19 vaccine. Shanghai-based Fosun did not answer questions about the announcement. China’s National Health Commission has directed questions to the country’s drug regulator, the National Medical Products Administration. The company did not respond to a fax request for comment.

Meanwhile, Abogen Biosciences hopes for a Chinese-developed mRNA vaccine center, a startup founded in 2019 by American-trained scientist Bo Ying, who once worked for Moderna. The company has partnered with more established companies in the country, such as Valvax, a non-governmental organization founded in 2001, and the Military Medical Research Facility Academy of Military Medical Sciences. Abogen has raised more than 7 1.7 billion since 2020. According to a study published in the Lancet Microbes Journal, a small, preliminary test among people designed to assess safety has found that the company’s vaccine candidates have achieved an immune response.

The results were “promising”, said Dr Binita Bal, who studied the immune system at the Indian Institute of Science Education and Research in Pune, India, although she said the shot triggered a direct comparison with Pfizer and Modern. Vaccines will help scientists better evaluate its effectiveness. But the large study needed to show whether the shot works to prevent infection or symptoms has not been completed. Abogen did not respond to requests for an interview.

Even if studies could be completed and the vaccine proved effective, creating the millions of doses needed would be a challenge, experts say. Abogen created a manufacturing facility in December 2020 with an estimated capacity of up to 120 million doses per year. Making that vaccine and ensuring quality on a scale will be a difficult hurdle because mRNA is still a new technology, says Scott Wheelright, chief operating officer of Bioinos Biosciences, a Chinese biopharmaceutical contract maker who has negotiated with Abogen.

Meanwhile, Chen, a health policy expert at Yale, said the Chinese government should better protect its aging population through both Pfizer vaccine approvals and booster shots. Using a Chinese phrase that means “completely abandoned,” Chen says the change doesn’t have to be “zero covid” all or nothing. “It doesn’t have to be Tang Ping or Zero Kovid,” Chen said. “I don’t think there are only two solutions, and we can be stuck in a middle ground.”

New Delhi: Brokerages like JPMorgan and Citi have maintained their positive position on Zomato; CLSA retains the purchase on () and upgrades to ‘Outperform’ for favorable risk-reward. BofA Securities maintained its neutral position, while Morgan Stanley began coverage of the chemical space, including three stocks.

JPMorgan says consistent Ebitda losses continue to decline

And with the return of the order, that Gross Order Value (GOV) has increased strongly. It said food supply earnings for Zomato rose again in the March quarter, as it suggested a price target of 130 130 on the stock.

Citi’s stock has a target price of Rs 80 to include FY22 numbers It also reported a 6 per cent hike in GOV and a consistent Ebitda loss of Rs 220 crore.

Morgan Stanley has started coverage in SRF with overweight position with a target of Rs 2,757. Start coverage on it

(Target Rs 954) and (Rs 4,562). Initiating coverage in the chemical sector, Morgan Stanley said the future of India’s specialty chemicals would look very different and the market was not setting prices at 200-600 basis points in exchange for equity expansion.

CLSA has upgraded three auto stocks because it thinks companies could benefit from falling steel prices, widening margins and a recovery after Covid-19.

What foreign brokers say in Zomato,

Shobha and 7 other stocks’.

The brokerage, meanwhile, has maintained its purchase at HAL with a target price of Rs 1,930 as FY24’s earnings assessment is 15 times cheaper. Towards the end of FY22, the PAT rose 17 percent, leading to a change in the balance sheet, foreign brokerages reported.

The same brokerage has upgraded Sobha to outperform with a target price of Rs 805 as it feels that the risk-reward is now favorable after the sharp fall in the stock. It slashed its presale estimate for FY23-FY24 by 13 percent and called the FY23 guidelines conservative.

BOFA Securities has remained neutral in Davis Labs with a target of Rs 4,300 crore as the risk of core earnings is running out. Custom synthesis drives revenue beat but the generic API remains weak, it says.

(Disclaimer: The recommendations, suggestions, opinions and opinions offered by the experts are their own. These do not represent the views of the Economic Times)

Product ocean shippers Diana Shipping (DSX) and Star Bulk career (SBLK) reported first quarter earnings on Tuesday. Both shipping stocks rose before the results and Diana Shipping was in a buying zone.


Demand for products such as coal, grain and chemicals remains high due to concerns over food and energy shortages, Russia’s invasion of Ukraine and the Kovid lockdown and pollution control in China’s economy, the two organizations said.

Diana shipping income

Estimate: Wall Street expects Diana Shipping to earn 28 cents per share, according to Factset, from a loss a year earlier. Revenue was expected to come in at $ 64.6 million, a 57% gain.

Results: Arrears before opening on Tuesday.

Diana Shipping stock rose 7.5% to 6.08 on the stock market today, matching the highest price since late 2015. DSX stock has now expanded slightly from the 5.78 entry in the cup-with-handle base.

Located in Greece, Diana Shipping operates about three dozen ships as of the fourth quarter. It owns or leases those ships Coal and iron ore, a major component needed to make steel, accounted for about 85% of the company’s cargo shipments last year. Cereals consist of about 9%.

Like other shipping stocks, Diana Shipping has a strong composite rating, at 99. Its EPS rating is 75.

Shipping stock and China, global demand

Russia’s aggression in Ukraine has cut off supplies and purchases of items such as oil and wheat, pushing up their prices. But China’s epidemic-related lockdowns – and the prospect of a reopening of its economy – have also added to the uncertainty surrounding its own demand for the product and the state of the world’s disrupted supply chain.

Problems above and below the supply chain have increased shipping costs. But some analysts say that last year container-shipping stock was more than one for bulk carriers. As a result, they say, the former tried to expand further than the latter, and thus the economy is more at risk for overcapacity if it turns south.

When Diana Shipping released its fourth-quarter results in February, management said “the war in Ukraine could have a broad-based negative impact on the dry bulk market and black sea ports shut down operations indefinitely.”

Diana also said at the time that China’s “disappointing” real estate market had reduced its chances of growth. And it noticed a decline in the country’s steel production last year, in an effort to reduce pollution, even as production increased in other countries.

Citing a study by shipping services company Clarksons, Diana Shipping said China’s iron ore exports would be “under pressure” this year.

Globally, Clarkson forecasts 2.2% growth for total dry-bulk trade this year, Star Bulk said in its own earnings call in February. Dry bulk refers to any material – such as grain or coal – that can be stored or shipped in bulk.

Star Bulk Income

Estimate: Wall Street expects Star Bulk to earn 47 1.47 per share, a 308% jump, over $ 288 million in earnings, an 85% gain.

Results: After closing.

Star Bulk stock rose 4.9% on Monday to close at 33.60, the highest hit since the end of 2014. Share Shave has a 98 composite rating and a 99 EPS rating.

Star Bulk operates a fleet of more than 120 ships. It is also located in Greece.

When Star Bulk reported its final round of earnings in February, it cited a number of factors that weighed on the dry-bulk trade earlier this year. Among them: Indonesia’s coal export ban in January, the Winter Olympics in China and severe weather in Brazil.

However, the company added that rising commodity prices have led producers to crank up production and others to secure a worldwide supply that is declining prematurely.

CEO Petraeus Pappas said, “High product prices provide a strong incentive for dry bulk cargo producers to expand output and exports in the next few years while stocks can only be replenished on a field basis at the right time.” In February

You may also like:

Warren Buffett Stocks: MSFT, GOOGL, FB out of 30 stocks on this screen.

XPEV stock sinks as protracted chip, China covid problem hits outlook of EV startup

Did Pfizer stock buy one after pediatric covid shots proved 80% effective?

The LNG Clean Energy Leader shows the pipe in the new breakout

Canada-headquartered Greenpower Motor Company, a manufacturer and distributor of electric medium and heavy-duty vehicles, has signed a joint venture with Jupiter Wagon Group (Jupiter Group) through its wholly owned subsidiary EA Green-Power (JV) to bring selected greenpower. All electric vehicles in the Indian market.

Jupiter manufactures railway wagons, passenger coaches, wagon components and castings in India, and counts the Ministry of Defense, the Ministry of Shipping, Tata Motors, Volvo Eicher Motors, Bharat Benz and Avia Motors among its leading customers.

Brendan Riley, President of GreenPower, said: “GreenPower has teamed up with Jupiter Wagon Group to bring GreenPower’s EV Star CC to the Indian market. We are excited to work with Jupiter to comply with a right-hand-drive version (homologate) of already proven and popular cars in North America. Both GreenPower and Jupiter believe that this zero-emission, battery-electric platform is exactly what is needed to provide a clean air solution for India and an affordable way to transport people and goods. This collaboration utilizes GreenPower’s proven EV capabilities and JWL’s production and distribution power. ”

The EV Star Cab and Chassis Right Hand Drive (EV Star CC RHD) is a purpose-built multi-utility zero-emission vehicle with a standard battery pack of 62.5 kWh, a payload of 4,095 kg and a 150 km range or an optional battery. The 118 kWh pack offers a payload of 3,675 kg and a range of 250 km.

EV Star Cab and chassis can be deployed for different mid and last mile delivery needs.

Priyankar Balekai, VP – Global Tracks, Greenpower says, “We have recently opened our office in Hyderabad and are excited to work with Jupiter to showcase the EV Star CC RHD in the Indian market, which is an unnecessary market for medium and heavy market. – Tariff all electric vehicles. “

NEW DELHI: Special chemical maker Ether Industries on Tuesday launched its initial public offering (IPO) for public bidding. Most analysts are happy with the company’s prospects and suggest subscribing to the issue.

Overall, the company plans to raise a little over Rs 808 crore through the initial route. However, the size of the new equity block has been slashed from Rs 757 crore, following its pre-IPO placement plan.

The issue includes issue of new equity shares worth Rs 627 crore and offer for sale (OFS) of 28.2 lakh equity shares up to Rs 181.04 crore by existing shareholders and promoters.

The price band for the sale of shares has been fixed at Rs 610-642. Bidders for the issue will be able to apply for 23 or more shares.

Analysts at Ventura Securities say the IPO is priced at Rs 642, while the Aether is priced at 32.2X FY24 P / E.

Recommended story back

“Pharma, Agrochemicals and FMCG consider the opportunity to grow specialty chemicals in the space and to improve the prospects for contract manufacturing and CRAMS under the Make-in-India initiative, we recommend a subscription rating,” they say.

The broker has already set a price target of Rs 797 for the stock, which represents a rise of 24 per cent over the 18-month IPO price.

Aether Industries focuses on advanced intermediate and specialized chemical production involving complex and varied chemicals and technologies. The company’s products find application in various fields such as pharmaceuticals, agrochemicals, specialties, electronic chemicals, material sciences, high-performance photography, etc.

Proceeds from the new issue will be used to fund capital expenditure requirements, loan repayments and working capital requirements for the proposed Greenfield project in Surat, Gujarat.

Amarjit S Maurya of Angel One says in terms of evaluation, the post-issue TTM P / E works at 75.6x (the upper end of the issue price band), which is reasonable considering its historical top-line and bottom-line. The CAGR at FY19-21 is 50 percent and 75 percent, respectively.

“It has a diverse customer base, strong financial track record and high ROE. Considering all the positive factors, we believe that this assessment is at a reasonable stage. As such, we recommend subscribing ratings to the issue, ”Maurya said.

According to analysts, the main positive aspects that can work for the company include:

  • Different portfolio of market-leading products
  • Focus on R&D to leverage key chemistry and technology skills
  • Strong and lasting relationship with diverse customer base
  • Synergistic business models focus on large-scale manufacturing, CRAMS and contract manufacturing.
  • Experienced evangelist and senior management with extensive domain knowledge

Key concerns that could derail a company’s growth are:

  • The business is dependent on production facilities and any shutdown or slowdown in manufacturing activities can adversely affect the company.
  • Currently, it generates the most revenue from the top 20 customers (73 percent) without a long-term contract with all of them.
  • Non-compliance and change of regulations may adversely affect its business.

The issue will close on Thursday, May 26th.

(Disclaimer: The recommendations, suggestions, opinions and opinions offered by the experts are their own. These do not represent the views of the Economic Times)

Gold market technical analysis

The gold market rallied to start the trading week on Monday after testing the 200-day EMA. At the moment, the market looks as if it is continuing to make a fuss, and I think we’ll see some hesitation and / or sell, it’s probably a matter of time. In the end, it will come down to the US dollar more than anything else and of course bond yields.

The 200-day EMA has a certain amount of psychological significance, so it is likely that we will see traders in this general vicinity attracted to the market. That being said, the level below $ 1800 has provided a significant amount of support, so we can try to get into some sort of consolidation phase before recovery.

A market break above the highs of Monday’s trading session would be a good sign, and it will almost certainly keep people in line with the 50-day EMA. Breaking above that then the market challenge has 1900. It’s a bit hasty to determine if this can happen, but it’s definitely something to keep in mind. Gold has a lot of influence, and at this point, if I could be a metal trader, it would be the gold of which I would be the buyer. Silver fading assemblies are actually more likely to be the business I take, or maybe some kind of “pair trade” when I sell silver and buy gold. All things being equal, we bought a little more so the pullback probably made sense regardless.

Gold Price Forecast Video 24.05.22

For a look at all of today’s economic events, check us out Economic calendar.

This article was originally posted on FX Empire

More from FXEMPIRE:

Singapore’s GIC Sovereign Wealth Fund will buy a 7.5 per cent minority stake in Aditya Birla Fashion and Retail Limited (ABFRL) for Rs 2,195 crore, Aditya Birla Fashion said in a statement on Tuesday. The fashion retailer said its board had approved the deal where the company would increase investment from a GIC-approved one by issuing equity and warrants on a priority basis. Following the transaction, Aditya Birla Group will hold about 51.9 per cent stake in the company. Shares of the company fell 0.61 percent in the first trading session on Tuesday.

Singapore’s GIC will now invest Rs 770 crore for equity and warrant subscriptions, and up to Rs 1,425 crore in one or more steps within 18 months of the transaction after warrant exercise, according to the statement.

“ABFRL has a strong track record of brand building and its new business line, which includes lingerie and ethnic clothing, has strong structured tailwinds. We are confident that the company is in a good position to continue its transformational journey into a future-ready consumer company driven by India’s growth, “said Chu Young Chin, Chief Investment Officer, GIC Private Equity.

Kumar Mangalam Birla, Chairman, Aditya Birla Group, said, “The Indian apparel industry is poised for long-term growth due to its strong core, favorable population, growing disposable income and aspiration for brands of a large and growing middle class.” “I am delighted to welcome GIC, a global institutional investor, as a long-term partner in the company’s exciting growth journey,” Birla added.

The retailer, which owns brands such as Louis Philippe and Allen Solly and recently acquired a stake in new-age brands such as House of Masabar, said it plans to use the raised capital to accelerate growth “built on the strengths of current business.” With the rise of the “emerging high-growth business model”.

The company plans to issue 1,02,16,450 equity shares at an issue price of Rs 288.75 per unit and 6,58,00,866 warrants at Rs 288.75 per piece. The company has announced an increase in authorized share capital from Rs 1,010.15 crore to Rs 2,010.15 crore. The company said the transaction was subject to regulatory and other formal approvals.

Font size

Ananta Rangaswamy, an advertising professional and journalist, died on Tuesday. Rangaswamy was the editor of Melt, an advertising and marketing magazine and portal.

Rangaswamy was the editor of CNBC TV18’s storyboard. Previously, he was the founding editor of Campaign India and senior editor of He has over 25 years of experience in companies such as Star TV, Sony Set and BCCL’s Times Television and Times FM. He has also served as Vice President of TBWA India.

Watching from the sidelines And The Elephants in the Room: The Future of Advertising in India He wrote two books.

Industry officials have expressed grief over Rangaswamy’s loss and went on social media to share the grief. “An advertising professional, salesperson, journalist, editor, event manager, he was a Maverick and always at the top of his game. A colleague and friend whom I have known for more than three decades was an outspoken, outspoken, well-meaning man. Miss you so much #AnantRangaswamy, “says Raj Nayak, founder,, social media platform Twitter.

“It is heartbreaking to hear about the death of Ananta Rangaswamy. An amazing person, an Adman (TBWA) journalist (former editor of Campaign India and CNBC TV18’s storyboard) and a man who has always stood up for his beliefs. He rested in eternal peace, “stated Lloyd Matthias, angel investor and business strategist.

Follow us TwitterInstagram, LinkedIn, Facebook